Holen Sie sich die Stockscreener-App
0.6419
2.74%
-0.0181
Handel nachbörslich:
.63
-0.0119
-1.85%
Schlusskurs vom Vortag:
$0.66
Offen:
$0.6734
24-Stunden-Volumen:
1.54M
Relative Volume:
0.10
Marktkapitalisierung:
$10.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.89M
KGV:
-0.2537
EPS:
-2.53
Netto-Cashflow:
$-11.95M
1W Leistung:
+3.48%
1M Leistung:
-14.41%
6M Leistung:
-50.24%
1J Leistung:
-70.28%
1-Tages-Spanne:
$0.6209
$0.7184
1-Wochen-Bereich:
$0.4924
$0.7184
52-Wochen-Spanne:
$0.284
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Vergleichen Sie PSTV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.6419 | 10.54M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by D Boral Capital - Defense World
Plus Therapeutics (NASDAQ:PSTV) Given Hold Rating at D. Boral Capital - Defense World
Plus Therapeutics (PSTV) Downgraded Amid Planned Reverse Stock S - GuruFocus
Colorectal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa - Barchart.com
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Plus Therapeutics (PSTV) Receives Downgrade to Hold by D. Boral Capital | PSTV Stock News - GuruFocus
PSTV Stock Sees Decline of Approximately -22.86% in Last Five Days - knoxdaily.com
Form 8-KCurrent report - ADVFN
Plus Therapeutics Inc (PSTV) can make a big difference with a little luck - Sete News
Investing in Plus Therapeutics Inc (PSTV): What You Must Know - knoxdaily.com
Plus Therapeutics Inc: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors - The Houston 100
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research
Plus Therapeutics adds Kyle Guse to its Board of Directors By Investing.com - Investing.com South Africa
Plus Therapeutics Inc (PSTV) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Plus Therapeutics adds Kyle Guse to its Board of Directors - Investing.com
Plus Therapeutics (PSTV) Welcomes Kyle Guse to Board as Audit Ch - GuruFocus
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins Its Board Of Directors - marketscreener.com
Plus Therapeutics Strengthens Board: Former Atossa CFO Brings 30 Years of NYSE and NASDAQ Leadership - Stock Titan
Plus Therapeutics (NASDAQ:PSTV) Price Target Raised to $20.00 at Ascendiant Capital Markets - Defense World
Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Rises By 34.5% - Defense World
Plus Therapeutics Appoints Kyle Guse to Board - MSN
Plus Therapeutics reports progress in CNS cancer treatment By Investing.com - Investing.com Canada
Plus Therapeutics Inc (NASDAQ: PSTV) Analysts Expect It Could Climb 89.63% From Current Levels. - stocksregister.com
Plus Therapeutics Presents New Data Highlighting Clinical Benefi - GuruFocus
Plus Therapeutics (PSTV) Unveils Promising Data on REYOBIQ at Upcoming Conference | PSTV Stock News - GuruFocus
Plus Therapeutics reports progress in CNS cancer treatment - Investing.com
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases - The Manila Times
Plus Therapeutics Presents New Data Highlighting Clinical - GlobeNewswire
New Cancer Drug REYOBIQ Achieves Breakthrough 86% Clinical Benefit in Brain Metastases Study - Stock Titan
Plus Therapeutics (PSTV) Plans Massive Stock Sale - GuruFocus
Plus Therapeutics Inc (PSTV) Volatility Hits 17.12% – Here Is What You Should Do - Stocksregister
Promising Outlook for Plus Therapeutics: Buy Rating Affirmed Amid Clinical and Financial Advancements - TipRanks
Plus Therapeutics: What’s Fueling the Surge? - timothysykes.com
PLUS THERAPEUTICS Inc. (PSTV) reports earnings - Quartz
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
What is HC Wainwright’s Estimate for PSTV FY2029 Earnings? - Defense World
HC Wainwright Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price - Defense World
Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL
Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com Australia
H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Canada
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):